1.	Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 116428, 2012-003438-18, NCT01767467
2.	Phase I/II Study of Adjuvant Dendritic Cell-Lymphoma Cell Hybrids and/or Dendritic Cells Pulsed With Tumor Lysates in Patients With Indolent B-Cell Lymphoma or Multiple Myeloma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MSCMI-40-2003, MSCMI 40/2003, EU-20913, NCT00937183
3.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
4.	Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 65 to 75 Sponsor: Other Protocol IDs: 05/10-L, NCT01146262
5.	Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: H-30087 TAIL, NCT01604031
6.	DC Vaccination for Postremission Therapy in AML Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: 2010-022446-24, NCT01734304
7.	Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: BP-HM-001, NCT01744223
8.	WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HaemaCBFWT102, Carreras 04/25f, NCT00153582
9.	Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: J05121 CDR0000492005, P30CA006973, JHOC-J05121, J05121, NCT00363649
10.	Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000540577, GIMEMA-CML0206, EUDRACT-2006-006189-40, EU-20724, CML0206, NCT00466726
11.	Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 09-412, NCT01096602
12.	Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-143, NCT01266083
13.	WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: RHMCAN0700, 2009-017340-14, ISRCTN62678383, NCT01334060
14.	Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: Over 65 Sponsor: Other Protocol IDs: CCRG12-001, NCT01686334
15.	GVAX vs. Placebo for MDS/AML After Allo HSCT Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-217, NCT01773395
16.	Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-196, NCT00442130
17.	A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Pro00001360, NCT00672152
18.	Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: O5CC14, EudraCT 2005-000806-29, GTAC GTAC098, NCT00718250
19.	Host Dendritic Cells in Allograft Patients Phase: Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 08-0906, NCT00935597
20.	Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: DCOne-1, NCT01373515
21.	Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation Phase: Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 36361, NCT01483274